MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

Search

Smith & Nephew PLC ADR

Отворен

33.14 -0.18

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

32.93

Максимум

33.25

Ключови измерители

By Trading Economics

Приходи

296M

Продажби

3B

P/E

Средно за сектора

29.196

89.037

Дивидентна доходност

2.33

Марж на печалбата

9.895

Служители

17,000

EBITDA

723M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+3.72% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.33%

2.18%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

14B

Предишно отваряне

33.32

Предишно затваряне

33.14

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Smith & Nephew PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.01.2026 г., 21:55 ч. UTC

Печалби

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22.01.2026 г., 23:52 ч. UTC

Печалби

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22.01.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22.01.2026 г., 23:40 ч. UTC

Пазарно говорене

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22.01.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.01.2026 г., 23:30 ч. UTC

Пазарно говорене

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22.01.2026 г., 22:37 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22.01.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

22.01.2026 г., 21:44 ч. UTC

Печалби

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22.01.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22.01.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22.01.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22.01.2026 г., 21:30 ч. UTC

Печалби

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Capital One To Acquire Brex >COF

22.01.2026 г., 21:13 ч. UTC

Печалби

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22.01.2026 г., 21:11 ч. UTC

Печалби

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22.01.2026 г., 21:11 ч. UTC

Печалби

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22.01.2026 г., 21:10 ч. UTC

Печалби

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22.01.2026 г., 21:06 ч. UTC

Печалби

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Rev $15.58B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q EPS $3.26 >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Net Interest Margin 8.26% >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Net $2.13B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Adj EPS $3.86 >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Net Charge-Offs $3.8B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Intuitive Surgical 4Q EPS $2.21 >ISRG

Сравнение с други в отрасъла

Ценова промяна

Smith & Nephew PLC ADR Прогноза

Ценова цел

By TipRanks

3.72% нагоре

12-месечна прогноза

Среден 34 USD  3.72%

Висок 34 USD

Нисък 34 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Smith & Nephew PLC ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

0

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

26.64 / 28.37Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat